Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 3/20 | 0.59 |
| ▸ | RPS6KB1 | P23443 | 3/20 | 0.59 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | GBA1 | P04062 | 2/20 | 0.51 |
| ▸ | EGFR | P00533 | 1/20 | 0.49 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.45 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.45 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | KCNN3 | Q9UGI6 | 1/20 | 0.44 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7837066 | 0.99 | AURKA (0.58) | AURKARPS6KB1AURKBLMNAGBA1 | |
| SCHEMBL20569405 | 0.82 | GBA1 (0.53) | AURKARPS6KB1AURKBLMNAGBA1 | |
| SCHEMBL22872944 | 0.81 | AURKA (0.53) | AURKARPS6KB1AURKBLMNAGBA1 | |
| SCHEMBL22872950 | 0.81 | AURKA (0.53) | AURKARPS6KB1AURKBLMNAGBA1 | |
| SCHEMBL22872897 | 0.81 | AURKA (0.53) | AURKARPS6KB1AURKBLMNAGBA1 | |
| SCHEMBL7822376 | 0.80 | KDM4C (0.46) | AURKARPS6KB1AURKBLMNAEGFR | |
| SCHEMBL7832386 | 0.80 | EGFR (0.54) | AURKARPS6KB1AURKBLMNAGBA1 | |
| Hydrochloric Acid SCHEMBL7821610 | 0.79 | KDM4C (0.45) | AURKARPS6KB1AURKBLMNAEGFR | |
| Hydrochloric Acid SCHEMBL7834199 | 0.79 | EGFR (0.53) | AURKARPS6KB1AURKBLMNAGBA1 | |
| SCHEMBL8930214 | 0.78 | AURKA (0.59) | AURKARPS6KB1AURKBLMNAEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0802914-B1 | ARYL- AND HETEROARYL- PURINE AND PYRIDOPYRIMIDINE DERIVATIVES | PHARMACIA & UPJOHN SPA (IT) | 2001-06-06 | — | — | EP | claimed |
| EP-3630759-B1 | COMPOUNDS USEFUL AS ION CHANNEL INHIBITORS FOR THE TREATMENT OF CANCER | CENTRE NAT RECH SCIENT (FR) | 2024-05-01 | — | — | EP | disclosed |
| US-20210009581-A1 | ION CHANNEL INHIBITOR COMPOUNDS FOR CANCER TREATMENT | CHU NANTES (FR) | 2021-01-14 | — | — | US | disclosed |
| EP-0802914-B1 | ARYL- AND HETEROARYL- PURINE AND PYRIDOPYRIMIDINE DERIVATIVES | PHARMACIA & UPJOHN SPA (IT) | 2001-06-06 | — | — | EP | disclosed |
| US-5965563-A | NOVEL PURINE DERIVATIVES SUCH AS N6-(2-OXINDOL-5-YL) ADENINE, METHODS OF SYNTHESIZING THEM; USE AS TYROSINE KINASE INHIBITORS | PHARMACIA & UPJOHN S.P.A. (IT) | 1999-10-12 | — | — | US | disclosed |
| EP-0802914-A1 | ARYL AND HETEROARYL PURINE COMPOUNDS | PHARMACIA & UPJOHN S.p.A. (IT) | 1997-10-29 | — | — | EP | disclosed |
| WO-1997018212-A1 | ARYL AND HETEROARYL PURINE COMPOUNDS | PHARMACIA & UPJOHN S.P.A. (IT) | 1997-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210009581-A1 | ION CHANNEL INHIBITOR COMPOUNDS FOR CANCER TREATMENT | CACNA1E, KCNA1, KCNT1 | AURKA 362/4885RPS6KB1 284/4885AURKB 530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.